Posted On: 12/14/2015 9:51:31 AM
Post# of 72446
Yes sir,
From Nov 23 PR.
"Phase 2 trial of Prurisol – Plaque Psoriasis
In addition, Cellceutix is pleased to announce that we have completed our goal of randomizing 100 subjects into the study, one month ahead of projections. Prurisol is an orally administered small molecule for the treatment of plaque psoriasis. This is a double-blind, placebo controlled study using three different dosages of Prurisol. Patients are required to receive double-blind therapy for 12 weeks and then return to the clinic four weeks later for a total duration in the study of 16 weeks."
From Nov 23 PR.
"Phase 2 trial of Prurisol – Plaque Psoriasis
In addition, Cellceutix is pleased to announce that we have completed our goal of randomizing 100 subjects into the study, one month ahead of projections. Prurisol is an orally administered small molecule for the treatment of plaque psoriasis. This is a double-blind, placebo controlled study using three different dosages of Prurisol. Patients are required to receive double-blind therapy for 12 weeks and then return to the clinic four weeks later for a total duration in the study of 16 weeks."
(0)
(0)
